Nicholas Hoffman & Company LLC. Sells 682 Shares of Sanofi (NASDAQ:SNY)

Nicholas Hoffman & Company LLC. decreased its stake in Sanofi (NASDAQ:SNY) by 2.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 25,014 shares of the company’s stock after selling 682 shares during the quarter. Nicholas Hoffman & Company LLC.’s holdings in Sanofi were worth $1,442,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNY. Fortitude Family Office LLC increased its position in shares of Sanofi by 708.6% in the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after buying an additional 659 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Sanofi by 69.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 56,230 shares of the company’s stock valued at $3,241,000 after acquiring an additional 23,138 shares during the period. Patriot Financial Group Insurance Agency LLC raised its position in shares of Sanofi by 9.0% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 21,025 shares of the company’s stock worth $1,212,000 after purchasing an additional 1,737 shares during the period. Concord Wealth Partners raised its position in shares of Sanofi by 157.8% during the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after purchasing an additional 363 shares during the period. Finally, First Bank & Trust lifted its holdings in shares of Sanofi by 5.0% during the 3rd quarter. First Bank & Trust now owns 59,267 shares of the company’s stock valued at $3,416,000 after purchasing an additional 2,801 shares in the last quarter. Institutional investors own 10.04% of the company’s stock.

Sanofi Stock Down 1.0 %

Sanofi stock opened at $53.83 on Wednesday. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a 1-year low of $44.05 and a 1-year high of $58.97. The company has a fifty day simple moving average of $56.06 and a 200 day simple moving average of $51.89. The company has a market cap of $136.61 billion, a P/E ratio of 27.46, a price-to-earnings-growth ratio of 1.55 and a beta of 0.60.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. The business had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a return on equity of 20.59% and a net margin of 9.96%. Sanofi’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.55 earnings per share. Research analysts anticipate that Sanofi will post 4.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on SNY shares. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday, October 14th. Argus upped their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Finally, Citigroup upgraded Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Sanofi currently has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.